Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850267 | PMC |
| http://dx.doi.org/10.1128/mBio.00514-16 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Factors associated with vaccine default in Southern Ghana based on data from the RTSS malaria vaccine trial in Cape Coast.
Sci Rep
January 2025
School of Public Health, University of Ghana, Accra, Ghana.
Malaria has been a severe global and public health concern for the last couple of decades. Ghana, like many other countries in sub-Saharan Africa, is most affected by the disease, with children facing dire consequences. The recent introduction of the RTS, S malaria vaccine holds great potential in reducing malaria fatalities in children.
View Article and Find Full Text PDFProduction and Purification of Plasmodium Circumsporozoite Protein in Lactococcus lactis.
Methods Mol Biol
February 2024
Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark.
Malaria is a vector-borne disease caused by Plasmodium parasites of which Plasmodium falciparum contributed to an estimated 247 million cases worldwide in 2021 (WHO malaria report 2022). The P. falciparum Circumsporozoite protein (PfCSP) covers the surface of the sporozoite which is critical to cell invasion in the human host.
View Article and Find Full Text PDFMalaria vaccine-related adverse events among children under 5 in sub-Saharan Africa: systematic review and meta-analysis protocol.
BMJ Open
October 2023
Department of Epidemiology and Disease Control, School of Public Health, College of Health Sciences, University of Ghana, Accra, Ghana
Introduction: The RTS,S vaccine has been approved for use in children under 5 living in moderate to high malaria transmission areas. However, clinically important adverse events have been reported in countries in sub-Saharan Africa. This systematic review aims to assess the frequency, severity and clinical importance of vaccine-related adverse events.
View Article and Find Full Text PDFMalaria vaccine coverage estimation using age-eligible populations and service user denominators in Kenya.
Malar J
September 2023
Population & Health Impact Surveillance Group, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.
Background: The World Health Organization approved the RTS,S/AS01 malaria vaccine for wider rollout, and Kenya participated in a phased pilot implementation from 2019 to understand its impact under routine conditions. Vaccine delivery requires coverage measures at national and sub-national levels to evaluate progress over time. This study aimed to estimate the coverage of the RTS,S/AS01 vaccine during the first 36 months of the Kenyan pilot implementation.
View Article and Find Full Text PDFImplementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report.
Malar J
August 2023
Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, Avenue Appia 20, 1211, Geneva 27, Switzerland.
A workshop on implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission, was held as a hybrid meeting in Dakar, Senegal, and online, 23-25 January 2023. Delegates from Expanded Programmes on Immunization (EPI) and National Malaria Control Programmes (NMCPs) from 13 African countries, and representatives from key stakeholders participated. RTS,S is the first malaria vaccine to be recommended by the World Health Organization (WHO).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!